Suppr超能文献

坦索罗辛治疗急性尿潴留男性患者的结果

Results of treatment with tamsulosin in men with acute urinary retention.

作者信息

Kim H L, Kim J C, Benson D A, Bales G T, Gerber G S

机构信息

Section Urology, Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA.

出版信息

Tech Urol. 2001 Dec;7(4):256-60.

Abstract

PURPOSE

The aim of this study was to prospectively assess the outcome in men treated with temporary catheter drainage and tamsulosin after an episode of acute urinary retention (AUR).

MATERIALS AND METHODS

Thirty-three consecutive men with AUR were treated with tamsulosin 0.4 mg daily for at least 4 days before a trial of voiding. Those men who were able to void adequately continued taking tamsulosin and were evaluated at 2-week and 3-month follow-up. After 3 months, additional follow-up was obtained at regular intervals as determined by the treating physician.

RESULTS

Median follow-up was 6.5 months. Mean urine volume at the time of initial bladder drainage was 790 mL. Eighty-eight percent (29/33) of men were able to void initially. Transurethral prostatectomy or intermittent catheterization were necessary in 9 (27%) of 33 patients during the follow-up period. A poor quality-of-life score on the initial International Prostate Symptom Score (p = .038) and a high postvoid residual volume 2 weeks after catheter removal (p = .013) correlated with failure of medical therapy. Patients with AUR after nonurologic surgery had a significantly better outcome than those with AUR that did not occur postoperatively. Mean symptom score, quality-of-life score, and postvoid residual urine volume were 12.9, 2.7, and 111 mL, respectively, at 2-week follow-up and were 11.9, 2.8, and 61.7 mL, respectively, at 3-month follow-up. Mean peak urinary flow rate at 3 months was 7.7 mL/s.

CONCLUSIONS

Tamsulosin appears to be helpful in the management of men with AUR. The majority of men were able to avoid surgery after temporary catheter drainage.

摘要

目的

本研究的目的是前瞻性评估急性尿潴留(AUR)发作后接受临时导尿管引流和坦索罗辛治疗的男性患者的预后。

材料与方法

33例连续性AUR男性患者在进行排尿试验前,每天服用0.4mg坦索罗辛至少4天。那些能够充分排尿的男性继续服用坦索罗辛,并在2周和3个月随访时进行评估。3个月后,根据主治医生的决定定期进行额外随访。

结果

中位随访时间为6.5个月。初次膀胱引流时的平均尿量为790mL。88%(29/33)的男性最初能够排尿。在随访期间,33例患者中有9例(27%)需要进行经尿道前列腺切除术或间歇性导尿。初始国际前列腺症状评分的生活质量评分较差(p = 0.038)以及拔除导尿管2周后的高残余尿量(p = 0.013)与药物治疗失败相关。非泌尿外科手术后发生AUR的患者的预后明显好于术后未发生AUR的患者。在2周随访时,平均症状评分、生活质量评分和残余尿量分别为12.9、2.7和111mL,在3个月随访时分别为11.9、2.8和61.7mL。3个月时的平均最大尿流率为7.7mL/s。

结论

坦索罗辛似乎有助于AUR男性患者的治疗。大多数男性在临时导尿管引流后能够避免手术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验